Company Overview and News

 
Stock investors are freaking out about bonds ending a 3 decadelong bull run—but should they be? - MarketWatch

2018-04-23 marketwatch
Government bond yields climbing and a shrinking gap between short-term and long-term Treasury rates have prompted some consternation on Wall Street, driving equity prices lower as investors fret about what these dynamics mean for U.S. economic growth as it enters its ninth year of expansion.
Upvote Downvote

3
Interest-rate worries may not be offset by good earnings news in the week ahead

2018-04-20 cnbc
Rising interest rates and inflation worries could hang over the stock market in the coming week, as investors look to a big flood of earnings news to lift some of their anxiety.
Upvote Downvote

 
Unum - Is It Time To Buy This Insurer?

2018-04-20 seekingalpha
I haven’t touched on the Company in some time, but last Summer I wrote that it was time to take profits on Unum (NYSE:UNM). I laid out the argument that at $48.86, the price was just too high. I asserted that Unum was riding the wave created by an increasingly Hawkish Federal Reserve which was propelling most financial stocks higher. I argued that weak top-line growth combined with the fact that increases in earnings per share, largely powered by share buy-backs, weren’t enough to justify the surge in valuation.
Upvote Downvote

 
Prudential’s Individual Annuities and Life Business

2018-04-20 marketrealist
Prudential Financial’s (PRU) individual annuities segment’s adjusted operating income rose by $119 million to $541 million in 4Q17 from $422 million in 4Q16. However, this amount includes the impact of significant items. If this impact is excluded, its operating income rose $103 million, boosted by policy fees.
Upvote Downvote

 
A Look at the PGIM Ultra-Short Bond ETF

2018-04-19 marketrealist
PGIM, which distributes Prudential Financial’s (PRU) retail products, has introduced the PGIM Ultra-Short Bond ETF, an actively managed fund focusing on capital appreciation and income generation. The diversified fund aims to manage risk.
Upvote Downvote

 
What Lies Ahead for Prudential Financial?

2018-04-19 marketrealist
Prudential Financial (PRU) has a positive outlook for its 2017 results. Despite being impacted by expenses in 4Q17, the company still has strong fundamentals. Wall Street analysts’ high and low EPS (earnings per share) estimates for Prudential are $3.10 and $2.61, respectively, for 1Q18. Their average estimate of $2.97 implies a quarter-over-quarter and year-over-year rise.
Upvote Downvote

 
 
MOVES-Prudential's PGIM names Ken Poliziani chief marketing officer

2018-04-17 reuters
April 17 (Reuters) - PGIM, the asset management arm of Prudential Financial, named Ken Poliziani as its first chief marketing officer.
Upvote Downvote

 
Weighing The Week Ahead: Do Stock Prices Already Reflect Strong Earnings?

2018-04-15 seekingalpha
The economic calendar is normal, with an emphasis on housing. Earnings season begins in earnest, with widespread, high expectations. Especially after Friday’s selloff, many will be wondering:
Upvote Downvote

 
Dow closes more than 200 points lower after Trump taunts Russia

2018-04-11 cnbc
Stocks fell on Wednesday after President Donald Trump taunted Russia on Twitter to "get ready" for a possible missile strike on Syria.
Upvote Downvote

 
The MnM Portfolio, Mar 2018 - A Leaner And Meaner Portfolio

2018-04-11 seekingalpha
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Upvote Downvote

 
U.S. companies found ways to avoid taxes before tax cut bill -report

2018-04-10 reuters
WASHINGTON (Reuters) - Fifteen U.S. corporations including online retailer Amazon.com Inc (AMZN.O), power company Duke Energy Corp (DUK.N) and insurer Prudential Financial Inc (PRU.N) avoided U.S. tax on nearly $25 billion in combined profits last year, a tax watchdog group said on Tuesday.
Upvote Downvote

 
Working in retirement can pay off big

2018-04-10 cnbc
When Jillian Cain retired at 62 from her job as an executive assistant, it gave her the opportunity to pursue another lifelong goal: selling photographs.
Upvote Downvote

 
Moving Average Crossover Alert: ING Group, N.V. (ING)

2018-04-09 zacks
ING Group, N.V. (ING - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ING broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
Upvote Downvote

 
Moving Average Crossover Alert: Arconic Inc. (ARNC)

2018-04-09 zacks
Arconic Inc. (ARNC - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ARNC broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 744320102